Vanguard Group Inc. Increases Stock Position in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Vanguard Group Inc. lifted its holdings in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 1.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,010,617 shares of the company’s stock after acquiring an additional 15,905 shares during the period. Vanguard Group Inc.’s holdings in Aligos Therapeutics were worth $755,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ALGS. Charles Schwab Investment Management Inc. purchased a new position in shares of Aligos Therapeutics during the second quarter worth approximately $30,000. PDT Partners LLC purchased a new position in shares of Aligos Therapeutics during the first quarter worth approximately $57,000. AQR Capital Management LLC purchased a new position in shares of Aligos Therapeutics during the second quarter worth approximately $58,000. Prelude Capital Management LLC purchased a new position in shares of Aligos Therapeutics during the first quarter worth approximately $58,000. Finally, State Street Corp grew its position in shares of Aligos Therapeutics by 60.2% during the first quarter. State Street Corp now owns 97,423 shares of the company’s stock worth $85,000 after acquiring an additional 36,600 shares during the last quarter. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Aligos Therapeutics Trading Down 10.5 %

Shares of ALGS opened at $0.89 on Tuesday. The firm has a market cap of $67.70 million, a PE ratio of -0.56 and a beta of 2.34. The company’s 50 day simple moving average is $0.89 and its 200-day simple moving average is $0.76. Aligos Therapeutics, Inc. has a 12-month low of $0.54 and a 12-month high of $1.38.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.05. Aligos Therapeutics had a negative return on equity of 116.41% and a negative net margin of 607.03%. The firm had revenue of $2.68 million during the quarter, compared to the consensus estimate of $3.20 million. As a group, equities research analysts forecast that Aligos Therapeutics, Inc. will post -0.83 EPS for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).